Clinical Trial Goal
To find out:
- The highest dose of ABBV-383 that’s safe to give
- If ABBV-383 is safe and works well to treat multiple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has relapsed or is refractory
- Have been treated with at least 2 treatments for multiple myeloma. Your doctor can tell you this
- Have not been treated with ABBV-383
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
ABBV-383 is a bispecific antibody targeting BCMA on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- ABBV-383 – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for about 3 years. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years.
The Food and Drug Administration (FDA) not yet approved ABBV-383.
Locations
Sponsors
lead: AbbVie
